Cellectis Q1 Revenue at $7.5M, Below Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 11 2026
0mins
Reports Q1 revenue $7.5M, consensus $9.37M. "The interim pivotal data published by Allogene on cema-cel, a product originally developed by Cellectis as UCART19, are a proud validation of our vision: that allogeneic, off-the-shelf cell therapy candidates could deliver transformative outcomes for cancer patients. We believe this approach has the potential to dramatically expand access to CAR-T beyond what autologous therapies can reach today" said Andre Choulika, Ph.D., Co-Founder and Chief Executive Officer of Cellectis. "As we look ahead to Q4 2026, with the expected interim pivotal Phase 2 data for lasme-cel in relapsed or refractory B-ALL, and the full Phase 1 dataset for eti-cel in relapsed or refractory NHL, Cellectis is approaching its own defining moment. We are excited about what lies ahead."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CLLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CLLS
Wall Street analysts forecast CLLS stock price to rise
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 3.630
Low
4.00
Averages
7.00
High
9.00
Current: 3.630
Low
4.00
Averages
7.00
High
9.00
About CLLS
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cellectis to Hold Annual General Meeting on June 25, 2026
- Annual Meeting Announcement: Cellectis has announced that it will hold its annual general meeting on June 25, 2026, at 2:30 p.m. CET at the Biopark auditorium in Paris, aiming to update shareholders on company developments and future strategies.
- Gene Editing Platform Advantage: As a clinical-stage biotechnology company, Cellectis leverages its pioneering gene-editing platform to develop life-saving cell and gene therapies, particularly showcasing unique competitive advantages in CAR T immunotherapies for oncology.
- End-to-End Control Capability: With in-house manufacturing capabilities, Cellectis is one of the few companies that can control the entire value chain of cell and gene therapies, providing it with a significant strategic position in the market.
- Global Business Presence: Cellectis is headquartered in Paris, France, with additional locations in New York and Raleigh, NC, demonstrating its global business expansion and market penetration capabilities.
See More
Cellectis Reports Q1 2026 Financial Results and Business Update
- Clinical Trial Progress: Cellectis' BALLI-01 trial for relapsed or refractory B-cell acute lymphoblastic leukemia shows a 100% objective response rate (ORR) in the target population, with the first interim analysis expected in Q4 2026, potentially paving the way for a future Biologics License Application (BLA).
- Favorable Safety Data: In the ALPHA3 trial for cema-cel, 58.3% of patients achieved minimal residual disease (MRD) negativity compared to 16.7% in the control group, with no serious adverse events reported, indicating strong safety and efficacy that could support future commercialization efforts.
- Strong Financial Position: As of March 31, 2026, Cellectis reported $188 million in cash and cash equivalents, providing a runway into Q4 2027; despite a $23 million decrease from 2025, the company demonstrates effective financial management.
- Increased R&D Spending: R&D expenses for Q1 2026 reached $27.2 million, up $5.3 million from the previous year, primarily due to increased personnel and external costs, reflecting the company's commitment to advancing its innovative therapies and enhancing future market competitiveness.
See More
Cellectis to Report Q1 2026 Financial Results on May 11
- Earnings Announcement: Cellectis has announced that it will report its Q1 2026 financial results on May 11, 2026, after the US market closes, demonstrating the company's commitment to transparency and timely information disclosure.
- No Conference Call: The company will not host a conference call to discuss the results, although the investor relations team will be available for questions, which may limit direct investor insights into the company's financial health.
- Gene Editing Platform: Cellectis leverages its pioneering gene-editing platform to develop life-saving cell and gene therapies, showcasing its innovative capabilities and market potential in oncology.
- End-to-End Control: As one of the few companies that control the entire value chain of cell and gene therapies, Cellectis' in-house manufacturing capabilities provide a competitive edge and strengthen its market position.
See More
Cellectis Highlights Allogene's Pivotal Trial Progress
- Clinical Trial Progress: Allogene Therapeutics' interim Event-Free Survival analysis from the ALPHA3 trial reveals that 58.3% of patients in the cema-cel arm achieved minimal residual disease (MRD) negativity, compared to 16.7% in the observation arm, indicating significant potential clinical benefits for this therapy in treating large B-cell lymphoma.
- Safety Assessment: As of the data cutoff, cema-cel treatment was generally well-tolerated, with 10 out of 12 patients managed in an outpatient setting post-infusion and no cases of cytokine release syndrome or other serious adverse events, demonstrating its safety in clinical applications.
- Market Potential: Cellectis is eligible for up to $340 million in development and sales milestone payments under the Servier Agreement, along with low double-digit royalties on net sales of cema-cel, highlighting its significant position in the cell therapy market.
- Future Outlook: Allogene anticipates completing study accrual by the end of 2027 and plans an interim Event-Free Survival analysis in mid-2027, with positive results potentially supporting a Biologics License Application (BLA), further advancing the commercialization of cema-cel.
See More
Cellectis SA Reports 2025 Financial Results and Clinical Updates
- Financial Overview: As of December 31, 2025, Cellectis SA reported cash and fixed-term deposits of $211 million, down from $264 million in 2024, indicating potential pressure on funding that could impact future R&D investments.
- Clinical Trial Progress: The Lasm cell candidate achieved a 100% overall response rate at the recommended Phase 2 dose in relapsed or refractory B-cell acute lymphoblastic leukemia, marking a significant breakthrough that may enhance the company's competitive position in the CAR T therapy market.
- Eisel Candidate Performance: Eisel demonstrated an 88% overall response rate and a 63% complete response rate in non-Hodgkin's lymphoma patients, providing encouraging preliminary results that could bolster investor confidence and support subsequent clinical trials.
- Market Challenges and Opportunities: Despite facing significant challenges in the biotech sector, Cellectis maintains strong partnerships with Allogene and Iovance, ensuring ongoing validation of its gene editing platform, with a potential BLA submission for Lasm cell expected in the second half of 2028, further expanding market opportunities.
See More
Cellectis to Announce Q4 Earnings on March 19
- Earnings Announcement: Cellectis is set to release its Q4 earnings on March 19 after market close, with investors keenly awaiting insights into its performance and future outlook.
- Earnings Expectations: The consensus EPS estimate stands at -$0.10, reflecting a 37.5% year-over-year improvement, indicating the company's efforts to enhance profitability.
- Revenue Forecast: The consensus revenue estimate is $12.47 million, representing a significant 62.5% year-over-year decline, highlighting the market challenges and sales pressures the company is currently facing.
- Historical Performance Review: Over the past year, Cellectis has beaten EPS estimates 50% of the time and revenue estimates 25% of the time, underscoring the uncertainty surrounding the company's earnings forecasts.
See More
Cellectis to Hold Annual General Meeting on June 25, 2026
- Annual Meeting Announcement: Cellectis has announced that it will hold its annual general meeting on June 25, 2026, at 2:30 p.m. CET at the Biopark auditorium in Paris, aiming to update shareholders on company developments and future strategies.
- Gene Editing Platform Advantage: As a clinical-stage biotechnology company, Cellectis leverages its pioneering gene-editing platform to develop life-saving cell and gene therapies, particularly showcasing unique competitive advantages in CAR T immunotherapies for oncology.
- End-to-End Control Capability: With in-house manufacturing capabilities, Cellectis is one of the few companies that can control the entire value chain of cell and gene therapies, providing it with a significant strategic position in the market.
- Global Business Presence: Cellectis is headquartered in Paris, France, with additional locations in New York and Raleigh, NC, demonstrating its global business expansion and market penetration capabilities.
See More
Cellectis Reports Q1 2026 Financial Results and Business Update
- Clinical Trial Progress: Cellectis' BALLI-01 trial for relapsed or refractory B-cell acute lymphoblastic leukemia shows a 100% objective response rate (ORR) in the target population, with the first interim analysis expected in Q4 2026, potentially paving the way for a future Biologics License Application (BLA).
- Favorable Safety Data: In the ALPHA3 trial for cema-cel, 58.3% of patients achieved minimal residual disease (MRD) negativity compared to 16.7% in the control group, with no serious adverse events reported, indicating strong safety and efficacy that could support future commercialization efforts.
- Strong Financial Position: As of March 31, 2026, Cellectis reported $188 million in cash and cash equivalents, providing a runway into Q4 2027; despite a $23 million decrease from 2025, the company demonstrates effective financial management.
- Increased R&D Spending: R&D expenses for Q1 2026 reached $27.2 million, up $5.3 million from the previous year, primarily due to increased personnel and external costs, reflecting the company's commitment to advancing its innovative therapies and enhancing future market competitiveness.
See More
Cellectis to Report Q1 2026 Financial Results on May 11
- Earnings Announcement: Cellectis has announced that it will report its Q1 2026 financial results on May 11, 2026, after the US market closes, demonstrating the company's commitment to transparency and timely information disclosure.
- No Conference Call: The company will not host a conference call to discuss the results, although the investor relations team will be available for questions, which may limit direct investor insights into the company's financial health.
- Gene Editing Platform: Cellectis leverages its pioneering gene-editing platform to develop life-saving cell and gene therapies, showcasing its innovative capabilities and market potential in oncology.
- End-to-End Control: As one of the few companies that control the entire value chain of cell and gene therapies, Cellectis' in-house manufacturing capabilities provide a competitive edge and strengthen its market position.
See More
Cellectis Highlights Allogene's Pivotal Trial Progress
- Clinical Trial Progress: Allogene Therapeutics' interim Event-Free Survival analysis from the ALPHA3 trial reveals that 58.3% of patients in the cema-cel arm achieved minimal residual disease (MRD) negativity, compared to 16.7% in the observation arm, indicating significant potential clinical benefits for this therapy in treating large B-cell lymphoma.
- Safety Assessment: As of the data cutoff, cema-cel treatment was generally well-tolerated, with 10 out of 12 patients managed in an outpatient setting post-infusion and no cases of cytokine release syndrome or other serious adverse events, demonstrating its safety in clinical applications.
- Market Potential: Cellectis is eligible for up to $340 million in development and sales milestone payments under the Servier Agreement, along with low double-digit royalties on net sales of cema-cel, highlighting its significant position in the cell therapy market.
- Future Outlook: Allogene anticipates completing study accrual by the end of 2027 and plans an interim Event-Free Survival analysis in mid-2027, with positive results potentially supporting a Biologics License Application (BLA), further advancing the commercialization of cema-cel.
See More
Cellectis SA Reports 2025 Financial Results and Clinical Updates
- Financial Overview: As of December 31, 2025, Cellectis SA reported cash and fixed-term deposits of $211 million, down from $264 million in 2024, indicating potential pressure on funding that could impact future R&D investments.
- Clinical Trial Progress: The Lasm cell candidate achieved a 100% overall response rate at the recommended Phase 2 dose in relapsed or refractory B-cell acute lymphoblastic leukemia, marking a significant breakthrough that may enhance the company's competitive position in the CAR T therapy market.
- Eisel Candidate Performance: Eisel demonstrated an 88% overall response rate and a 63% complete response rate in non-Hodgkin's lymphoma patients, providing encouraging preliminary results that could bolster investor confidence and support subsequent clinical trials.
- Market Challenges and Opportunities: Despite facing significant challenges in the biotech sector, Cellectis maintains strong partnerships with Allogene and Iovance, ensuring ongoing validation of its gene editing platform, with a potential BLA submission for Lasm cell expected in the second half of 2028, further expanding market opportunities.
See More
Cellectis to Announce Q4 Earnings on March 19
- Earnings Announcement: Cellectis is set to release its Q4 earnings on March 19 after market close, with investors keenly awaiting insights into its performance and future outlook.
- Earnings Expectations: The consensus EPS estimate stands at -$0.10, reflecting a 37.5% year-over-year improvement, indicating the company's efforts to enhance profitability.
- Revenue Forecast: The consensus revenue estimate is $12.47 million, representing a significant 62.5% year-over-year decline, highlighting the market challenges and sales pressures the company is currently facing.
- Historical Performance Review: Over the past year, Cellectis has beaten EPS estimates 50% of the time and revenue estimates 25% of the time, underscoring the uncertainty surrounding the company's earnings forecasts.
See More
